“So, altogether, we still do point to an operating margin of greater than 43% in the year 2025.”

In context

“global sales, again, at the start of next year will drive significant gross margin improvement. At the same time, we will be investing in our business. We will be disciplined in that investment, but we are investing in the portfolio of products that we have in the market and that we will be launching, as well as investing in our robust and growing pipeline and that obviously includes the Daiichi collaboration, where we have noticed we expect about a $0.25 impact as a result of investing predominantly in the research and development of a wide range of programs, that Dean has partially outlined, as well as this financing costs. We also have made significant progress across our pipelines with many other collaborations, acquisition and the progress we are making with our own internal assets. So, altogether, we still do point to an operating margin of greater than 43% in the year 2025. However, we will not forgo necessary investments in our business to progress our pipeline to ensure that we have advance healthcare and drive growth, which really is our priority. Rob Davis: Great. Thank you, Seamus. Next question please. Julie. Operator: Thank you. Our next question comes from Terence Flynn with Morgan Stanley. Your line is open. Terence Flynn: Great. Thanks so much for taking the question. I guess, another one for Dean on the TROP2 landscape. I know you guys talked over the weekend about your first Phase 3 trial in lung cancer here. Maybe just any more context on the decision to pursue the EGFR mutant population, given what you are seeing from the landscape out there, including some of the Astra data and then what that means for the front-line setting as you try to craf”